Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.36 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713804 | 0.92 | AKR1C3 (0.42) | AKR1C3AKR1C2CTSSCTSKNOTUM | |
| SCHEMBL20032372 | 0.90 | AKR1C3 (0.39) | AKR1C3AKR1C2SCN9A | |
| SCHEMBL20032482 | 0.84 | TRPV1 (0.36) | GCGR | |
| SCHEMBL20032350 | 0.82 | PTGS2 (0.34) | LMNA | |
| SCHEMBL18713986 | 0.82 | AKR1C3 (0.42) | AKR1C3AKR1C2SCN9A | |
| SCHEMBL18713979 | 0.82 | KCNH2 (0.38) | AKR1C3AKR1C2CTSSCTSKGCGR | |
| SCHEMBL21507822 | 0.80 | KDM4E (0.43) | AKR1C3AKR1C2NOTUMTMPRSS4CCR2 | |
| SCHEMBL21725513 | 0.80 | KCNH2 (0.35) | AKR1C3AKR1C2LMNACCR2 | |
| SCHEMBL20032375 | 0.80 | TRPV1 (0.36) | LMNA | |
| SCHEMBL21366928 | 0.79 | KCNH2 (0.43) | KDM4EGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | AKR1C3 157/4885AKR1C2 103/4885CTSS 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.